- 13 min ago Pranjal Patil, First Blind Woman IAS Officer Takes The Charge Of Sub-Collector At Thiruvananthpuram
- 1 hr ago Karwa Chauth 2019: This Karwa Chauth Spruce Up Your Look With These Stunning Hairstyles
- 2 hrs ago Happy Birthday Hema Malini: Five Times Dream Girl Inspired Us With Her Gorgeous Saris
- 2 hrs ago Esther Duflo Wins Her Nobel As An Economist And Not As Abhijit Banerjee's Wife
- Technology Hike Becomes One Of The Top Three Patent Filers In India
- Movies 21 Years Of Kuch Kuch Hota Hai: Karan Johar Gets Emotional; Says 'Firsts Are Always Special'
- News Haryana elections: Average assets of re-contesting MLAs grew by 32 per cent
- Automobiles 2020 Tata Nexon Spied Testing Ahead Of Launch In India: Spy Pics & Details
- Sports ISL 2019-20: Mumbai City FC Team preview: Strength, weakness, squad, key players, stats, prediction
- Finance Ensure This Condition Is Met As Else Your EPF Interest Will Not Be Credited
- Travel 8 Romantic Getaways Near Mumbai: From Hill Sations To Beaches
- Education Why Is World Students' Day Celebrated On APJ Abdul Kalam's Birthday?
Metformin is an inexpensive, generic drug that helps patients prevent dangerously high blood sugar levels. It will work nearly twice as long, for the people who are taking it within three months of their diabetes diagnosis. To gain the full benefit from metformin, patients should start taking it as soon as they find out they have diabetes. Starting the drug early preserves the body's own ability to control blood sugar, which in turn prevents the long-term complications of diabetes like heart disease, kidney failure, and blindness.
Metformin is recommended as a first-line agent in the treatment of type 2 diabetes, but in most patients it eventually stops working, forcing them to take additional medications to control their blood sugar. Each additional drug adds extra costs and the possibility of more side effects including weight gain. So this study becomes a welcome news for newly diagnosed patients.
This study, named 'The Kaiser Permanente' study, is the first to compare failure rates of metformin in real-world setting. This study has appeared in the March issue of Diabetes Care, a journal of the American Diabetes Association.